A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study

References

• Gratwohl A, Baldomero H, Passweg J, Frassoni F, Niederwieser D, Schmitz N, . Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003;17:941–59.
   PubMed Web of Science ®Google Scholar
• Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, . Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283:845–8.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Srbic K, Seggewiss R, Topaly J, Ho AD. Functional characterization of podia formation in normal and malignant hematopoietic cells. J Leuk Biol 2002;71:425–32.
   PubMed Web of Science ®Google Scholar
• Nie Y, Han YC, Zou YR. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008;205:777–83.
   PubMed Web of Science ®Google Scholar
• Foudi A, Jarrier P, Zhang Y, Wittner M, Geay JF, Lecluse Y, . Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4–/– chimeric mice. Blood 2006;107:2243–51.
   PubMed Web of Science ®Google Scholar
• Dabusti M, Lanza F, Campioni D, Castagnari B, Tieghi A, Moretti S, . CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies. J Hematother Stem Cell Res 2003;12:425–34.
   PubMedGoogle Scholar
• Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, . Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728–30.
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, . Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307–18.
   PubMed Web of Science ®Google Scholar
• Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, . AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006;107:3772–8.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, . Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009;113:6215–24.
   PubMed Web of Science ®Google Scholar
• Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, . Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295–300.
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, . The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867–74.
   PubMed Web of Science ®Google Scholar
• Dipersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, . Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720–6.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Seeger T, Maier P, Li L, Weinhardt S, Laufs S, . The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006;34:1052–9.
   PubMedGoogle Scholar
• Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, . Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007;109:2708–17.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Ehninger G, Hübel K, Topaly J, Goldschmidt H, Ho AD, . Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant. 2009 Jul 13. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Larochelle A, Vormoor J, Hanenberg H, Wang JC, Bhatia M, Lapidot T, . Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nature Med 1996;2:1329–37.
   PubMed Web of Science ®Google Scholar
• Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38− progenitor cells. Blood 1991;77:1218–27.
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213–26.
   PubMedGoogle Scholar
• Fruehauf S, Haas R, Conradt C, Murea S, Witt B, Mohle R, . Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995;85:1219–31.
   Google Scholar
• Keeney M, Brown W, Gratama J, Papa S, Lanza F, Sutherland DR. Single platform enumeration of viable CD34(pos) cells. J Biol Regul Homeost Agents 2003;17:247–53.
   PubMedGoogle Scholar
• Punzel M, Liu D, Zhang T, Eckstein V, Miesala K, Ho AD. The symmetry of initial divisions of human hematopoietic progenitors is altered only by the cellular microenvironment. Exp Hematol 2003;31:339–47.
   PubMedGoogle Scholar
• Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, . Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2006;78:21–8.
   PubMedGoogle Scholar
• Kerre TC, De Smet G, De Smedt M, Offner F, De Bosscher J, Plum J, . Both CD34+38+ and CD34+38– cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion. J Immunol 2001;167:3692–8.
   PubMed Web of Science ®Google Scholar
• Bellucci R, De Propris MS, Buccisano F, Lisci A, Leone G, Tabilio A, . Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant 1999;23:1–8.
   PubMed Web of Science ®Google Scholar
• Mohle R, Pforsich M, Fruehauf S, Witt B, Kramer A, Haas R. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant 1994;14:827–32.
   PubMed Web of Science ®Google Scholar
• Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993;177:1331–42.
   PubMed Web of Science ®Google Scholar
• Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, . AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002–12.
   PubMed Web of Science ®Google Scholar
• Oelschlaegel U, Bornhauser M, Boxberger S, Kroschinsky F, Illmer T, Hoelig K, . Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol 2007;86:569–73.
   PubMedGoogle Scholar
• Schols D, Este JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147–56.
   PubMed Web of Science ®Google Scholar
• Aiuti A, Tavian M, Cipponi A, Ficara F, Zappone E, Hoxie J, . Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol 1999;29:1823–31.
   PubMed Web of Science ®Google Scholar
• Kahn J, Byk T, Jansson-Sjostrand L, Petit I, Shivtiel S, Nagler A, . Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 2004;103:2942–9.
   PubMed Web of Science ®Google Scholar
• Bonig H, Priestley GV, Papayannopoulou T. Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. Blood 2006;107:79–86.
   PubMedGoogle Scholar
• Sutherland HJ, Eaves CJ, Lansdorp PM, Thacker JD, Hogge DE. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991;78:666–72.
   PubMed Web of Science ®Google Scholar
• Hess DA, Bonde J, Craft TP, Wirthlin L, Hohm S, Lahey R, . Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007;13:398–411.
   PubMed Web of Science ®Google Scholar
• Haas R, Witt B, Mohle R, Goldschmidt H, Hohaus S, Fruehauf S, . Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995;85:3754–61.
   PubMed Web of Science ®Google Scholar
• Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, . Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990–8.
   PubMed Web of Science ®Google Scholar
• Henon P, Sovalat H, Bourderont D, Ojeda-Uribe M, Arkam Y, Wunder E, . Role of the CD34+ 38– cells in posttransplant hematopoietic recovery. Stem Cells 1998;16(Suppl. 1):113–22.
   PubMedGoogle Scholar
• Fruehauf S, Schmitt K, Veldwijk MR, Topaly J, Benner A, Zeller WJ, . Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999;105:786–94.
   PubMed Web of Science ®Google Scholar
• Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074–81.
   PubMed Web of Science ®Google Scholar